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ABSTRACT:
Autoimmune and paraneoplastic encephalitides are a group of neurologic disorders that present with cognitive decline,
neuropsychiatric symptoms, movement disorders, or seizures. These diseases can present before, with, or after the
diagnosis of malignancy. We report two cases of GABA-B encephalitis from Pakistan. The first patient was a 67-year-old
gentleman presented with cognitive decline and neuropsychiatric symptoms. His CSF analysis showed increased
protein levels and GABA-B receptor antibodies. He was treated with pulse steroids, which improved his symptoms. The
second patient was a 34-year-old lady with cognitive decline and psychomotor symptoms. Her serum autoimmune
antibody panel showed antibodies against GABA-B receptors. She was treated with pulse steroids followed by plasma
exchange, but did not improve. A low threshold should be kept for testing for autoimmune and paraneoplastic
encephalitides because they are potentially treatable.
KEYWORDS: autoimmune encephalitis, paraneoplastic encephalitis, GABA-B, cognitive decline, neuropsychiatric
manifestations.
CASE REPORTS:
Patient 1:
A 67 year old gentleman presented with increasing
forgetfulness, difficulty recognizing familiar people,
reduced verbal output, visuospatial dysfunction, visual
hallucinations and sleepiness for one month. He had a
history of diabetes, hypertension, Bell’s palsy, benign
prostatic hyperplasia, presbycusis and hypothyroidism.
He had been prescribed antipsychotics and
antidepressants by a psychiatrist with some
improvement in his behavior. However, his cognition
had not improved. The neurologic examination was
significant for orofacial dyskinesia and a mini-mental
state examination score of 24, with impaired
registration, recall, and attention and calculation. He
had a normal EEG. His contrast enhanced MRI brain
showed chronic microvascular changes and age related
atrophy. His CSF analysis showed a normal white cell
count (<5 cells/µL), normal glucose 64 mg/dL), raised
proteins (83.2 mg/dL) and antibodies positive against
GABA-B receptors (shown in Figure). All other
laboratory and CSF markers were normal. There was no
evidence of an underlying neoplasm on a CT chest with
contrast.
He
was
treated
with
pulsed
methylprednisolone (1 gram/day) for 3 days followed by

INTRODUCTION:
Autoimmune encephalitides are a group of neurologic
diseases that affect the limbic system in response to
infectious or autoimmune triggers. Some of these
diseases have an association with cancers, and may
present as paraneoplastic syndromes1. Several
autoimmune encephalitides are characterized by
antibodies that target neuronal cell surface receptors or
synaptic proteins2. Many of these tumors may be
treated by steroids, intravenous immunoglobulins,
plasma exchange, rituximab, or cyclophosphamide3.
Because these diseases are potentially treatable, a
high index of suspicion is required to prevent neurologic
morbidity. One such autoimmune encephalitis is
GABA-B encephalitis, which presents with symptoms of
limbic encephalitis, such as seizures, cognitive decline,
and behavioral problems. It may also present with
ataxia or opsoclonus-myoclonus4. Although the exact
cause of GABA-B encephalitis is unclear, it may be
preceded by systemic or neurologic viral infections or
have no obvious trigger5. This diagnosis should be
particularly considered in middle-aged or older adults
with new-onset seizures and multiple neurologic
manifestations6. Here, we present two cases of GABA-B
encephalitis.
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anti GABABR encephalitis is 66 years with an almost
equal incidence in males and females8. Similarly, in our
patients, the mean age was 50.5 years with an equal
gender distribution. However, this is a report of two
patients only. Therefore, conclusions should be drawn
with caution. The most common presenting symptom is
seizures8, however, none of our patients had seizures
during the disease course. Patient 1 presented with
memory
dysfunction
and
neuropsychiatric
disturbances, whereas Patient 2 presented with
behavioral problems.

oral prednisolone (1 mg/kg/day). His symptoms
improved rapidly and he was started on azathioprine
with gradual tapering of prednisolone. However,
tapering of prednisolone led to relapse of symptoms so
he is being managed on fortnightly methylprednisolone
with azathioprine and a gradual tapering of the oral
steroids. At the last follow-up, the patient’s neurologic
and psychiatric symptoms had markedly improved.
Patient 2:
A 34 year old lady presented with progressively
worsening memory for recent events, repetition of
speech, visual hallucinations, delusions, disinhibition,
psychomotor agitation and urinary and fecal
incontinence for a year. She did not have any past
medical history of note. Her initial neurological
examination and workup was normal. Her serum
autoimmune antibody profile showed antibodies
against GABA-B receptors (shown in Figure). It is
important to note that anti-GABA-B antibodies should
preferably be checked in the CSF. However, this patient
had refused CSF analysis. Therefore, the antibodies
were checked in the serum. She was managed with
methylprednisolone (1 gram/day) for 5 days followed by
oral steroids. The patient did not improve so plasma
exchange was done. She was advised rituximab for
maintenance therapy, but her family declined further
treatment due to financial reasons. Her follow-up
evaluation revealed a static neurological condition.

Around 50% of the patients with anti-GABA-B
antibodies have an underlying small cell lung cancer9.
However, both our patients were negative for
malignancy after extensive workup. Anti-GABA-B
encephalitis is also associated with presence of
antibodies against other intracellular neuronal antigens
like amphyphysin, Ri (ANNA2) and SOX-19. Patient 1
had negative test result for an immunoblot panel of
nine antibodies against intracellular neuronal antigens
PNMA2, amphyphysin, CV2, Ri, Yo, Hu, Recoverin ,
SOX-1 and titin.
Around 60 to 70% of patients with anti-GABA-B
encephalitis show complete or partial response to
immunosuppressive therapy10. Patient 1 showed
complete recovery with parenteral and oral steroids.
However, Patient 2 did not improve with steroids and
plasma exchange. Because of financial issues, Patient
2 and her family refused further treatment.

DISCUSSION:
The incidence of anti GABA-B antibody positivity in
patients tested for autoimmune encephalitis related
antibodies is around 0.2%7. We tested 640 samples
(both sera and CSF) for autoimmune encephalitis
associated antibodies from January 2015 to October
2019 and 2 (0.3%) were positive for anti GABA-B
antibodies. According to the most recent published
literature, the median age of patients presenting with

CONCLUSION
In conclusion, anti-GABA-B encephalitis represents a
potentially treatable cause of cognitive decline and
neuropsychiatric disturbances. A high index of
suspicion should be kept for GABA-B and related
encephalitides as they present with a diverse range of
symptoms.
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Figure. Indirect Immunofloresence using U90 cells
(Euroimmun, Leubeck Germany) transfected with
genes of GABAB receptors, showing anti GABAB
receptor antibodies. Non transfected cells were used
as negative control.
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